Sciensus Names James Tugendhat CEO, Succeeding Interim Chief Gordon Cox

Sciensus has appointed James Tugendhat OBE as chief executive officer, succeeding Gordon Cox, who held the role on an interim basis during the Board's search and remains chief operating officer. PR Newswire announced the appointment on October 28, 2026.

Tugendhat's Move From HC-One to Sciensus

Tugendhat brings more than 20 years of leadership experience across healthcare and complex service organisations, according to the announcement. He was most recently Group CEO of HC-One, described as the UK's largest care home operator.

His earlier roles include senior positions at Bupa, among them CEO of Health Dialog, a US health analytics and chronic disease management company. He also served for seven years as a non-executive director of the Royal Free London NHS Foundation Trust.

Peter Nicklin, Chairman of Sciensus, said: "We're delighted to welcome James to Sciensus. He understands what it takes to run a regulated, people-centred healthcare business, and he brings extensive experience of the wider healthcare sector." Nicklin also thanked Cox for his leadership and contributions over the previous months.

Tugendhat said: "Sciensus plays a vital role in helping patients access specialist medicines and care, including treatments that can be delivered in their own homes." He said he would work with colleagues across the business and build on the expertise already in place to support patients, healthcare providers and biotech and pharmaceutical partners.

Sciensus Leadership Appointments in 2026

According to akta.pro company records, Sciensus appointed Annabelle Newman as General Counsel and Group Company Secretary in March 2026 to lead legal, governance and company secretarial functions. In January 2026 the company appointed Julie Gosper as Managing Director of its Rare and Specialty business unit, bringing 20 years of commercial strategy experience from Clinigen.

The same records list Christian Tucat as Chief Executive Officer and Sameer Mistry as Chief Medical Officer in the company's leadership. Sciensus was founded in 1995 and is headquartered in London.

Earlier Sciensus Executive Hires

Sciensus appointed John Gillie as chief financial officer effective June 1, 2026, EIN Presswire reported; Gillie brought more than 34 years of life sciences finance experience, including CEO roles at Quinecsa Solutions and Envision Pharma. In May 2026, EIN Presswire reported that Sciensus appointed Dr Sameer Mistry as chief medical officer, bringing more than 25 years of experience across the NHS, pharmaceutical and medtech sectors.

Sciensus Homecare Partnership With Novocure

In August 2026, EIN Presswire reported that Sciensus and Novocure announced a partnership to deliver Tumour Treating Fields therapy for glioblastoma, mesothelioma and non-small cell lung cancer to eligible private patients in the UK.